SAB Biotherapeutics Inc. (NASDAQ: SABS) Stock Information | RedChip

SAB Biotherapeutics Inc. (NASDAQ: SABS) Listen to this Section


$2.40
+0.1500 ( +6.67% ) 7.0K

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Market Data


Open


$2.40

Previous close


$2.25

Volume


7.0K

Market cap


$22.38M

Day range


$2.25 - $2.63

52 week range


$2.16 - $10.50

Insider Ownership Transactions

Total Amount Purchased: -8,442,973.00 | $ -20,263,135.20

Date Type Amount Purchased Purchaser
2024-02-23 Sale -115000.00 King Michael
2024-02-23 Sale -140000.00 Bausch Christoph Lawrence
2024-02-23 Sale -434000.00 Reich Samuel J
2024-02-23 Sale -140000.00 Kropotova Alexandra
2024-02-23 Sale -190000.00 Sullivan Eddie Joe
2023-12-08 Buy 1740.00 Sullivan Eddie Joe
2023-11-30 Buy 11000.00 Reich Samuel J
2023-11-30 Buy 5000.00 King Michael
2023-11-28 Sale -4584571.00 Moin Andrew
2023-11-28 Sale -2857142.00 Ellias Helen K.

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Jul 17, 2024
4 Insider transactions 1 Jul 17, 2024
4 Insider transactions 1 Jul 17, 2024
8-k 8K-related 11 Jun 27, 2024
3 Insider transactions 1 Jun 24, 2024
8-k 8K-related 14 May 31, 2024
def Proxies and info statements 4 May 30, 2024
8-k 8K-related 12 May 21, 2024
10-q Quarterly Reports 88 May 20, 2024
nt Quarterly Reports 1 May 15, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.